Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8274)	5/6/2003 6:00:47 PM
From: WhatsUpWithThat	Respond to of 52153

I have no knowledge, education or expertise with which I can personally judge the science (so what the heck am I doing in biotech, you might ask? ;-) ONCY/TSE:ONC has been working extensively with the reovirus, unmodified, for some time now. PI complete, PII on glio underway (currently on hold to allow an unspecified change in procedure). Mice? That's old ;-) More detail on the StockHouse ONC thread. Am interested in all opinions, esp given the depth of knowledge evident on this thread as I've read it over time. Best regards WUWT

To: Biomaven who wrote (8274)	5/6/2003 6:46:00 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Peter >> This is interesting. I predict we are going to hear a lot more about the retinoblastoma (Rb) pathway over the next few years, although I don't know of any public biotechs currently doing much with Rb (Titan and Onyx have dabbled with it I think).>> Thanks for pointing that out. I would have missed it. :-). As a matter of fact Titan's share price has been relatively strong over the last couple of days going from 1.60 to 1.90 under much higher turnover than normal. There might be a connection to the research you referred to. On the other hand RB94, as the product is called, does not seem to have been considered as one of their hotter properties. On the website they say that they are looking for any further development to be funded from external sources. (Which is of course completely in line with Titan's general modus of operation). Erik